Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week
Revolution Medicines wrapped up Friday with a 10.7% gain, closing at $118.64. The cancer-drug developer remains in focus amid ongoing takeover buzz heading into next week. Shares fluctuated between $109.88 and $125.79, with roughly 20.8 million shares changing hands.
